NCT04640545View on ClinicalTrials.gov

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

May 12, 2020

Primary Completion Date

August 19, 2024

Study Completion Date

August 19, 2024

Conditions
Advanced Melanoma
Interventions
DRUG

LBL-007

LBL-007 will be administered intravenously every two weeks (Q2W) .

DRUG

Toripalimab

Toripalimab Injection will be administered by intravenously (Q2W) .

DRUG

Axitinib Tablets

Axitinib Tablets On-demand administration

Trial Locations (8)

100142

Beijing Cancer Hospital, Beijing

130021

Jilin Cancer Hospital, Changchun

the First Hospital of Jilin University, Changchun

210008

Nanjing Drum Tower Hospital, Nanjing

350000

Fujian Cancer Hospital, Fuzhou

410006

Hunan Cancer Hospital, Changsha

430022

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

610041

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Nanjing Leads Biolabs Co.,Ltd

INDUSTRY

NCT04640545 - A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma | Biotech Hunter | Biotech Hunter